Pulmonary arterial hypertension among HIV-infected children: results of a national survey and review of the literature

Arnaud Grégoire L’Huillier, Klara Maria Posfay-Barbe*, Hiba Pictet and Maurice Beghetti

1 Pediatric Infectious Diseases Unit, Department of Pediatrics, Geneva University Hospitals, Geneva, Switzerland
2 Faculty of Medicine, University of Geneva, Geneva, Switzerland
3 Pediatric Cardiology Unit, Department of Pediatrics, Geneva University Hospitals, Geneva, Switzerland

Since the advent of highly active anti-retroviral therapy, HIV-related mortality has decreased dramatically. As a consequence, patients are living longer, and HIV infection is becoming a chronic disease. Patients and caretakers have to deal with chronic complications of infection and treatment, such as cardiovascular diseases, which now represent an important health issue, even in the pediatric population. Prevalence of pulmonary arterial hypertension (PAH) in the adult HIV population is around 0.4–0.6%, which is around 1000- to 2500-fold more prevalent than in the general population. In recent adult PAH registries, HIV has been identified as the fourth cause of PAH, accounting for approximately 6–7% of cases. Therefore, regular screening is recommended in HIV-infected adults by many experts. If HIV-associated PAH is mainly reported in HIV-infected adults, pediatric cases have also been, albeit rarely, described. This scarcity may be due to a very low PAH prevalence, or due to the lack of systematic cardiovascular screening in pediatric patients. As PAH may manifest only years or decades after infection, a systematic screening should perhaps also be recommended to HIV-infected children. In this context, we retrospectively looked for PAH screening in children included in our national Swiss Mother and Child HIV cohort study. A questionnaire was sent to all pediatric infectious disease specialists taking care of HIV-infected children in Switzerland, part of the Swiss Mother and Child HIV (MoCHIV) cohort. The questions tried to identify symptoms suggestive of cardiovascular risk factors and asked which screening test was performed. In the 71 HIV-infected children for which we obtained an answer, no child was known for PAH. However, only two had been screened for PAH, and the diagnosis was not confirmed. In conclusion, PAH in HIV-infected children is possibly underestimated due to lack of screening. Systematic echocardiographic evaluation should be performed in HIV-infected children.

Keywords: human immunodeficiency virus, pediatrics, pulmonary artery hypertension, screening, survey

Because of the lack of randomized control studies, it is difficult to differentiate the etiological role of the virus itself from the impact of HAART in pulmonary arterial hypertension (PAH), as well as other cardiovascular manifestations. PAH is a serious disease of the pulmonary arteries characterized by vascular remodeling due to dysfunctional proliferation of smooth muscle and endothelial cells. It leads to an increase in pulmonary vascular resistance and pulmonary arterial pressure (PAP). PAH classification was updated during the World Symposium on Pulmonary Hypertension in 2013. This classification gives more importance to pediatric PAH compared to the previous Danapoint Classification.

Despite this, no systematic cardiovascular screening is usually suggested to HIV-infected children. To demonstrate this, we sent a questionnaire to all infectious diseases specialists taking care of HIV-infected children in Switzerland, part of the Swiss Mother and Child HIV (MoCHIV) cohort study to evaluate if they look for PAH symptoms and perform screening procedures. We will first review HIV-related
PAH (HIV-PAH) and second describe the results of our questionnaire.

**EPIDEMIOLOGY**

Pulmonary arterial hypertension was described in HIV-infected patients for the first time in 1987 (13). Since then, HIV has been identified as one of the associated forms of PAH, accounting for approximately 6–8% of cases (14–17). However, because of the high HIV prevalence worldwide and the poor screening, HIV-PAH may be an important unrecognized cause of PAH. Even if confounding factors, such as drug use and co-infection with hepatitis C virus (HCV) have been reported (18), more than 80% of PAH cases in the HIV population are directly related to HIV and/or its treatment (19, 20).

Pulmonary arterial hypertension is defined as a resting PAP > 25 mmHg, associated with a pulmonary arterial occlusion pressure (PAOP) < 15 mmHg (21). HIV-PAH diagnosis can only be confirmed once all other possible etiologies have been excluded.

Diagnosis relies on clinical symptoms, such as fatigue and dyspnea, as well as clinical findings, such as an increase in the pulmonary component of the second heart sound, a tricuspid regurgitation murmur or a right fourth heart sound, and signs of right heart failure. Chest X-ray may show cardiomegaly and pulmonary arteries enlargement, and the electrocardiogram shows right ventricular hypertrophy with right axis deviation. When PAH is suspected, echocardiography is the most useful diagnostic tool (22). Confirmation with right heart catheterization (RHC) is the gold standard. Some authors recently proposed a diagnosis algorithm (23, 24).

Prevalence of HIV-PAH is around 0.2–0.6% (20, 23, 25–30), which is 1000- to 2500-fold more prevalent than in the general population (20, 23). However, as PAH may present with very scarce symptoms and no systematic screening is usually offered in the HIV-infected population, these results are probably underestimated. Most previously mentioned studies included only symptomatic patients. When all HIV-infected patients of a cohort are included and/or when using only echocardiography without RHC confirmation, HIV-PAH prevalence reaches 2.5–10% (18, 29, 31–33). Compared to patients with HIV-PAH diagnosed using RHC, mean PAP values were 20 mmHg higher when diagnosis was established only with echocardiography, suggesting that echocardiography overestimates PAP (22). Hsue et al. described pathological PAH by echocardiography in 35% of their HIV-infected cohort (14). In a recent study, HIV-PAH prevalence was 57%, but only patients with tricuspid regurgitation were included and methods to calculate PAP were different (34).

**PHYSIOPATHOLOGY AND HISTOLOGICAL FEATURES**

HIV-related PAH physiopathology is not completely understood, is probably multifactorial, and includes genetic factors. It is hypothesized that HIV acts as a trigger, maintaining chronic inflammation and immune activation. Histological features, which closely resemble those seen in idiopathic PAH, show in most cases a pulmonary arteriopathy with so-called “plexiform lesions” associated with concentric laminar intimal fibrosis, medial hyperplasia, and white cells. They suggest chronic inflammation (13, 19, 20, 28, 35–38). Occasionally, plexiform lesions are lacking, possibly because it is an earlier stage of the disease (39). More rarely, thrombotic arteriopathy of the small vessels has been described (40). As simian immunodeficiency virus (SIV) infection of macaques shares many characteristics with HIV infection, these animals have been used as non-human primate model of HIV: plexiform lesions were only recovered among macaques infected with SHIV, a viral construct containing the HIV Nef protein in an SIV backbone, but not among SIV alone-infected macaques (41). In contrast, in another animal study, all SIV and SHIV macaques had elevated PAP associated with histological changes consisting mostly of intimal and medial hyperplasia. PAP values were higher in SIV and SHIV macaques than in healthy macaques, and PAP increased as early as 3 months after SIV infection (42).

HIV was never detected – to our knowledge – in the pulmonary endothelial cell using different techniques, such as immunohistochemistry, HIV-DNA hybridization, electron microscopy, or PCR. The absence of virus in endothelial cells, but its presence in alveolar macrophages, suggests an indirect action through mediator release rather than a direct endothelial infection (39, 43–45). Absence of virus in endothelial cells has also been described in SIV (46).

Endothelial dysfunction in PAH is characterized by a reduced production of vasodilators prostacyclin and nitric oxide (NO) and an increased production of endothelin-1 (ET-1) (47), a potent vasoconstrictor: its importance in idiopathic PAH pathol-ogy has been widely studied (48). Pellicelli et al. demonstrated increased levels of ET-1, IL-6, and TNF-alpha among HIV-PAH patients compared to HIV-infected patients without PAH. They also showed that plasmatic concentrations of ET-1 and IL-6 were correlated to severity of HIV-PAH (49).

The role of viral proteins has also been studied. Despite the absence of virus in endothelial cells, HIV envelope protein Gp120 has been shown to be toxic in vitro by inducing pulmonary endothelial cells apoptosis and time- and dose-dependent increase in ET-1 (50, 51). Moreover, Gp120 activates T lymphocytes (52) and increases TNF-alpha production (51), which sustains inflammation and may play a subsequent role in HIV-PAH development. Another recent study has shown that Gp120 stimulates arteri- oal smooth muscle cells to a express tissue factor, initiating the coagulation cascade (53). Other HIV viral proteins, such as Nef and Tat, lead to chronic inflammation and endothelial dysfunction and may play a role in HIV-PAH development. Nef was shown to increase monocyte migration, enhancing local inflammation (54). Moreover, Nef was detected in lungs endothelial cells from HIV-PAH patients, but not among healthy or idiopathic PAH patients, suggesting that while the virus does not enter endothelium, it is possible that secreted viral proteins do (41). A group recently showed that the risk of HIV-PAH was related to the number of Nef mutations and that some polymorphisms mapped to Nef functional domains were overrepresented among HIV-PAH patients (55, 56).

Tat is another viral protein secreted by HIV-infected cells, which stimulates endothelial cells, enhancing vascular permeability via IL-6 (57). It has been suggested that Tat induces chronic inflammation and endothelial dysfunction (58). Once the endothelium is damaged, exposure of vascular smooth muscle cells to viral proteins such as Tat down regulates antiangiogenic factor BMPR:
this promotes vascular smooth muscle cells proliferation and hypertrophy (59).

Similarly, HIV-1 proteins expression increased pulmonary vascular resistance among rats exposed to chronic hypoxia compared to wild-type rats (60).

Levels of asymmetric dimethylarginine (ADMA), an endothelial NO synthase inhibitor, are increased during HIV infection because of sustained inflammation. This may contribute to endothelial dysfunction, as ADMA levels are correlated with PAP in HIV-infected patients (61). Platelet-derived growth factor (PDGF) can induce proliferation and migration of smooth cells: Humbert et al. found that PDGF expression was increased in perivascular areas of the lungs of HIV-PAH patients (43). Similarly, increased vascular endothelial growth factor (VEGF) expression in HIV-infected patients may alter vascular permeability and induce endothelial cells (62). As only a small proportion of patients develop HIV-PAH, a genetic predisposition is assumed, such as the reported association between HIV-PAH and HLA DR6 and DR52 alleles (63). Despite being identified in 70% of familial PAH and 20% of idiopathic PAH, no BMPR-2 mutation has been identified among HIV-PAH patients (25).

Other factors may contribute to HIV-PAH pathophysiology. HCV infection or drug use are independent etiologies of PAH; however, as they are more frequent among HIV-infected patients, they may act as confounding factors (18, 20). Cool et al. showed the presence of human herpes virus-8 (HHV-8) in lung lesions of patients with idiopathic PAH (64). This was not confirmed in other studies on idiopathic PAH patients (65) and in HIV-PAH patients, despite their immunosuppression (14, 66). Immune restoration in mice infected by Pneumocystis jiroveci has been shown to increase the risk of persistent PAH. However, the persistence of PAH after treatment suggests that chronic inflammation is the most important factor rather than acute infection itself (67).

CLINICAL PRESENTATION

Clinically, symptoms of HIV-PAH are similar to idiopathic PAH. Early HIV-PAH may be misdiagnosed because of non-specific symptoms, such as exercise intolerance, progressive dyspnea (85%), edema (30%), and non-productive cough (19%) (19). With the progression of the disease, signs of right ventricular dysfunction appear. Compared to idiopathic PAH, patients reported in the literature are usually younger (mean age 33 years) (19) and less symptomatic (35, 68). Males are proportionally more affected (male: female ratio 1.5:1 compared to 1:1.7 in idiopathic PAH), reflecting the prevalence of the HIV population (19). Moreover, time between symptoms and diagnosis is generally shorter than in idiopathic PAH: possibly a consequence of closer follow-up (25).

HIV-related PAH carries a poor prognosis: mortality is mainly due to PAH rather than to HIV complications: PAH is therefore a predictor of mortality by itself (20, 25, 26, 68). Initial studies reported a median survival between 0.5 and 2.7 years (19, 27), and only 21–46% median survival at 3 years (19, 25–27). Earlier studies reported a faster progression (35) and a shorter survival with HIV-PAH compared to idiopathic PAH (20, 35). This could be explained by a more prevalent and severe ventricular systolic dysfunction among HIV-PAH patients compared to patients with PAH of other etiologies (69). More recent studies have shown a slightly improved median survival with 66–86% at 3 years (17, 70, 71). As many deaths in these recent studies were unrelated to PAH, one may suppose a decrease in HIV-PAH-related death (71). Survival significantly decreases with an increase of NYHA stages; therefore, a clinical marker of HIV-PAH progression (25, 68), would be crucial to identify patients in the early, scarcely symptomatic phase of the disease.

The relationship between the severity of HIV and PAH is subject to debate. HIV-PAH occurs at all stages of HIV infection. Most authors could not show an association between HIV-PAH and low CD4 T cell count (19, 20, 23, 27, 34, 68), even if the proportion of patients with CD4 count <200/mm3 was higher among HIV-PAH patients in one study (23). On the other hand, other groups described an increased survival rate with increasing CD4 counts (17, 25, 26).

Regarding viremia, several studies could not find an association with HIV-PAH (23, 34, 68) but others described an increased survival with lower viremia (17, 71). Finally, in one study, viremia was higher among HIV-PAH patients than among HIV patients without PAH (18). To date, there are no sufficient data to confirm a protective role of HIV control through HAART on HIV-PAH’s incidence and progression.

TREATMENT OF HIV-PAH

Because survival is related to NYHA stage, early diagnosis and treatment are paramount (25, 68). There are no current validated guidelines and HIV-PAH treatment is still controversial because of the lack of randomized studies.

Non-specific treatment

Oxygen reduces hypoxia-induced pulmonary vasoconstriction, whereas diuretics reduce right ventricular preload, and digoxin increases cardiac output. Oral anticoagulation reduces the possible thrombotic component of PAH (72), but its use for HIV-PAH is often limited due to concomitant thrombocytopenia and hepatopathy. Calcium channel blockers (CCB) use has been disappointing in adult HIV-PAH because almost all patients are not responders to acute vasoreactivity testing, it lacks a sustained vasodilator effect and has important side-effects (26), possibly related to interactions with HAART (73). Given that a positive acute vasoreactivity response to CCB is more frequent in children than adults and that there is no pediatric data concerning CCB use in HIV-PAH, these medications should be considered in selected cases, but vasoreactivity is not common in HIV-PAH.

Specific treatment

Prostacyclin analogs can be administered by IV infusion, inhalation, or subcutaneously.

Epoprostenol, the intravenous form of a prostacyclin analog, has been shown to induce clinical (25, 74) and hemodynamic improvement (25, 35, 74), especially when combined to HAART (25). Epoprostenol has been shown to increase survival (25). Its administration mode requires the use of a central venous catheter, which is linked with risks of infection and of misuse in drug abusers. Inhaled iloprost also showed hemodynamic (27, 75, 76) and clinical (75, 76) improvement,
albeit not statistically significant. Subcutaneous treprostinil increases hemodynamic and clinical parameters (77) in HIV-PAH patients.

Sildenafil, a phosphodiesterase inhibitor type 5, is the most frequently used medication in idiopathic PAH. In HIV-PAH, its use is limited because of its interaction with protease inhibitors (PIs), through the 3A4 P450 cytochrome pathway (78–80). However, in case reports of patients with HIV-PAH, it showed clinical and hemodynamic improvement (81–83).

Bosantan, an oral dual endothelin receptor antagonist, acts by inhibiting the potent vasoconstricting properties of endothelin. Bosantan has been shown to induce a clinical and hemodynamic improvement among HIV-infected patients (26, 71, 84, 85). Some patients even normalized their hemodynamic values during treatment (71). In 2012, Tcherakian et al. reported two cases of sustained and completely reversible HIV-PAH with bosantan treatment, persisting after drug discontinuation (86). Bosantan is a moderate Cytochrome P450 3A4 and C09 inducer, therefore simultaneous administration of anti-retroviral drugs should be performed with caution (87).

A treatment algorithm was recently proposed for HIV-PAH (88).

ROLE OF HAART IN HIV-PAH

The role of HAART in PAH is unclear. As chronic inflammation probably contributes to HIV-PAH pathophysiology, one may suspect a beneficial effect of HAART on HIV-PAH by reducing inflammation. In rats, PIs reverse or decrease PAH progression by reducing remodeling and smooth muscle cell proliferation (89). In humans, some authors showed no change in the frequency or severity of PAH since HAART was introduced, or in patients treated with HAART (17, 18, 23, 26), whereas others described a decrease of PAH incidence (27, 90) associated with a decline in HIV-PAH-related mortality (25, 27, 71). Among patients with HIV-PAH, clinical improvement was observed, especially when associated to PAH medications (17, 85). In a similar fashion, hemodynamics improved with HAART whether or not associated to PAH medication (26, 27, 85, 91). It is possible that PIs may be the most beneficial (27).

On the other hand, other studies have shown a deleterious effect of HAART on HIV-PAH, possibly secondary to PI-induced endothelial dysfunction (92). In vitro studies have demonstrated that anti-retrovirals, especially PIs, increased ET-1 production, followed by endothelial and vascular smooth muscle cell proliferation (93). Among rats, administration of AZT and PIs was associated to endothelial dysfunction and an increase in ET-1 production (94). In humans, some authors describe stable HIV-PAH after HAART interruption (95), while others describe an increased incidence with HAART compared to ART (96, 97) or an accelerated HIV-PAH evolution (44). Reinsch et al. reported an increased echocardiographically proven HIV-PAH prevalence among patients treated with HAART compared to naive patients (31). Another human study associated ritonavir-boosted PIs and abacavir with HIV-PAH (34).

In general, HIV-PAH prevalence has not changed significantly since HAART was introduced. This may suggest that antiviral drugs have a little effect on sites where the virus affects vascular cells. However, a protective effect of HAART on survival and incidence may explain a stable prevalence, as patients are now living longer. In clinical practice, since the Opravil et al. study showing an improvement of the pressure gradient when the patients were treated, experts recommend to introduce HAART at the time of HIV-PAH diagnosis, regardless of CD4 T-cell counts (26).

PEDIATRIC DATA

While HIV-PAH mainly concerns HIV-infected adults, pediatric cases have also been described (63, 83, 98–104), the youngest being between 1 and 2 years old (83, 102). Apart from HIV infection, few of these children also have other PAH predisposing factors, such as hemophilia (99, 101). The youngest patient is an HIV-infected very-low birth-weight infant, which presented with neonatal PAH: his condition resolved with HAART treatment but confounding factors, such as persistent ductus arteriosus, prolonged mechanical ventilation, extreme prematurity, systemic infection, and persistent pulmonary hypertension of the newborn, may have contributed to the disease (105). The causality is therefore uncertain. In a cohort of pediatric PAH patients in the Netherlands, 1% of cases were infected with HIV (98). In vertically HIV-infected children in Thailand, more than 40% presented echocardiographic criteria for HIV-PAH, but in more than half of the cases, this could be explained by lymphoid interstitial pneumonia (106). More recently, Ferrand et al. diagnosed HIV-PAH by echocardiography in 7% of vertically infected adolescents (aged 10–19 years) from Zimbabwe (107). Cunha et al. described an echocardiographic prevalence of HIV-PAH in 4.4% of a Brazilian children cohort younger than 13 years (108). Two studies in Thailand and Zimbabwe including only symptomatic HIV-infected toddlers have described an HIV-PAH prevalence of 48–75% (109, 110). The prevalence of echocardiographic HIV-PAH among children is similar or even higher than in adult reports using only echocardiography as a diagnostic tool. This high prevalence among HIV-infected children in Asia, Africa, and South America may be explained by vertical transmission. A delayed HIV diagnosis such as described in Ferrand et al. (median age at diagnosis 12 years) may also have contributed to the high HIV-PAH prevalence (107). Finally, confounding factors, such as high prevalence of parasitic diseases, chronic hepatitis B and C infection, and high seroprevalence of HHV-8 could have played a role.

In a recent registry study of more than 360 children in 19 countries – including Switzerland – with confirmed PAH, there was no HIV-infected child (111). Similarly, there was no HIV-infected patient in another registry study including more than 200 children with PAH (112). This may be due to the fact that no systematic screening is performed in the HIV-infected population but also to a selection bias of both registries and their participating centers as almost all patients were symptomatic.

WHAT IS DONE IN SWITZERLAND?

To demonstrate a correlation between HIV and PAH in HIV-infected children, we retrospectively analyzed cardiovascular and, in particular, PAH screening of children in the Swiss MoCHIV cohort study.
**Questionnaire on the screening of pulmonary arterial hypertension (PAH) in a cohort of HIV-infected children**

Each form corresponds to a patient with HIV

---

| Date of birth | Hospital Center |
|---------------|-----------------|
|               | GE: Genève, LS: Lausanne, ZH: Zurich, BS: Basel, SG: St-Gall, BE: Bern |

1) Type of current antiretroviral treatment:  
- NRTI  
- NNRTI  
- IP  

2) Was there a screening of PAH?  
- yes  
- no  

3) Is the child affected by PAH?  
- yes  
- no  

   a) At what age the first symptoms have been observed?  
   - years  

   b) What was the clinical presentation?  
   - Dyspnoea  
   - Hemoptysis  
   - Chest pain  
   - Dizziness  
   - Syncope  
   - Pedal edema  
   - Increased intensity of P2  
   - Palpable P2  
   - A right ventricular lift  
   - Pulmonic ejection sound  

   c) Date of diagnosis  
   - D D M M Y Y  

   d) Which additional exams have been performed?  
   - ECG  
   - Chest radiography  
   - Ecocardiography  
   - Scintigraphy  
   - Six-minute walk test  
   - Cardiac catheterization  
   - Acute vasodilator testing  

   e) Has a etiological check-up been performed?  
   - yes  
   - no  

   f) Functional class NYHA * at diagnosis  
   - I  
   - II  
   - III  
   - IV  
   - I don’t know  

   g) Type of antiretroviral treatment at early symptoms of PAH  
   - NRTI  
   - NNRTI  
   - IP  

   h) Rate of CD4 at early symptoms of PAH  
   - mm³  

   i) Current treatment for PAH  
   - yes  
   - no  

   j) Improvement of symptoms since the introduction of the treatment for PAH  
   - yes  
   - no  

4) For patient not known for PAH  
   a) Has PAH been investigated?  
   - yes  
   - no  

   b) Are there any suggestive signs or symptoms of PAH?  
   - Dyspnoea  
   - Hemoptysis  
   - Chest pain  
   - Dizziness  
   - Syncope  
   - Pedal edema  
   - Increased intensity of P2  
   - Palpable P2  
   - A right ventricular lift  
   - Pulmonic ejection sound  

* Functional Class NYHA: I = no symptoms with ordinary activity; II = symptoms with ordinary activity; III = symptoms with less than ordinary activity; IV = symptoms with any activity or at rest

---

Thank you for returning the forms before the 1/04/2013 to the following address: Prof M. Beghetti, Hôpital des enfants, 6 rue Willy-Donizetti, 1211 Genève 14

Thank you for your collaboration. For any questions, please contact Hiba Khiai 076-4257334 hibiakhiai@gmail.com

---

**FIGURE 1** | Questionnaire sent to Swiss pediatric infectious diseases specialists following HIV-infected children.
The MoCHIV Cohort Study is a merger of the former Neonatal HIV Study and the Swiss HIV and Pregnancy Study. Initially, the main goal was to collect a maximum of data in children born to HIV-infected mothers and HIV-infected children to gain epidemiological information and to study vertical transmission and natural history of disease. In 1998, a merged project was built named The Swiss MoCHIV Study. In 2004, a permanent link was established between the Swiss HIV Cohort Study (SHCS) and MoCHIV. Thus, longitudinal data in women included in both cohorts became available for research, making MoCHIV a very unique mother–child cohort. All mothers and children are given a cohort number, which is then used to collect data in both cohorts anonymously. Women and children are followed according to good clinical practices, as defined by the respective guidelines for adults, pregnant women, and children. These have been regularly adjusted according to growing knowledge.

It is estimated that approximately 75% of HIV-infected children living in Switzerland are part of MoCHIV. All Swiss pediatric infectious disease experts following HIV-infected children in the cohort received a person-specific questionnaire. The questions concerned symptoms suggestive of PAH and which cardiovascular screening was performed. In addition, questions concerning HIV status (CD4 T-cell count, viremia, HAART treatment or not) were recorded (Figure 1).

Among the 83 children currently included in the MoCHIV cohort study, the questionnaire was retrieved for 71 (86%) children. As suspected, no child of the MoCHIV cohort was known for PAH. Only two children (3%) had been screened for PAH, one because of thoracic pain and one because of dizziness, but diagnosis was not confirmed. Echocardiographic studies have reported higher prevalence of PAH (106–110). It is therefore possible that HIV-PAH is under-diagnosed in Switzerland as well because systematic screening is not performed. Only symptomatic cases would be (or will be) detected. Alternatively, it is also possible that other cofactors are involved and explain the higher prevalence in other countries.

CONCLUSION
Increased PAH risk in HIV-infected children, due to HIV infection and/or anti-retroviral treatment, creates new challenges and has serious implications for the quality of life and the survival of this population. However, despite a clearly increased risk, PAH detection is neglected in HIV-infected children. The true impact of PAH can only be appreciated after years or decades because of its silent and slow progression. Survival among HIV-infected children will probably continue to increase with more potent treatment options. As demonstrated in several studies, the prevalence of echocardiographic signs of increased PAP despite being below PAH definition level is more frequent than expected, even in children. Therefore, a systematic PAH screening should be proposed in this at-risk population (113–117). An echocardiography should be performed in all HIV-infected children at least once. However, a regular echocardiographic follow-up would be even more helpful, despite its cost, because there is a better outcome when diagnosis is early. RHC should be offered to all patients with abnormal echocardiographic findings. This has been successfully done in adult patients with sickle cell disease or scleroderma, another pathology associated with PAH (118, 119). Moreover, because only a proportion of HIV-infected patients develop HIV-PAH, finding biomarkers predicting HIV-PAH would be essential for the future.

ACKNOWLEDGMENTS
The authors acknowledge all members of the MoCHIV cohort study who answered our questionnaire, especially Jean-Jacques Cheseaux, Claire-Anne Wyler, David Nadal, Christian Kahlerd, Andrea Duppenthaler, and Christoph Rudin.

REFERENCES
1. WHO. Progress Report 2011: Global HIV/AIDS Response. Geneva: World Health Organisation (2011). p. 1–233.
2. Hladik F, McElrath MJ. Setting the stage: host invasion by HIV. Nat Rev Immunol (2008) 8(6):447–57. doi:10.1038/nri2302
3. Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 infection. N Engl J Med (2011) 364(20):1945–54. doi:10.1056/NEJMoa1118741
4. Baccetti P, Moss AR. Incubation period of AIDS in San Francisco. Nature (1989) 338(6212):251–3. doi:10.1038/338251a0
5. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuerher J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med (1998) 338(13):853–60. doi:10.1056/NEJM199806123381301
6. van Rossum AM, Fraaij PL, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis (2002) 2(2):93–102. doi:10.1016/S1473-3099(02)00183-4
7. Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage GR III, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med (2001) 345(21):1522–8. doi:10.1056/NEJMoa011157
8. Lobne N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med (2007) 146(2):87–95. doi:10.7326/0003-4819-146-2-200701160-00003
9. Haas B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis (2011) 53(11):1130–9. doi:10.1093/cid/cir626
10. Archer S, Rich S. Primary pulmonary hypertension: a vascular biology and translational research "work in progress". Circulation (2008) 102(22):2781–91. doi:10.1161/01.CIR.102.22.2781
11. Simonneau G, Gatzoulis MA, Adatia I, Gelernter DJ, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol (2013) 62(25 Suppl):D34–41. doi:10.1016/j.jacc.2013.10.029
12. Ivey DD, Abman SH, Barst RJ, Berger RM, Bonnet D, Fleming TR, et al. Pediatric pulmonary hypertension. J Am Coll Cardiol (2013) 62(25 Suppl):D317–26. doi:10.1016/j.jacc.2013.10.028
13. Kim KK, Factor SM. Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome. Hum Pathol (1997) 18(12):1293–6. doi:10.1006/hnpp.1997.0077
14. Quezada M, Martin-Carbonero L, Soriano V, Vispo E, Valencia E, Moreno V, et al. Prevalence and risk factors associated with pulmonary hypertension...
in HIV-infected patients on regular follow-up. AIDS (2012) 26(11):1387–92. doi:10.1097/QAD.0b013e328354f5a1

19. Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest (2000) 118(4):1133–41. doi:10.1378/chest.118.4.1133

20. Mesa RA, Edell ES, Dunn WF, Edwards WD. Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. Mayo Clin Proc (1998) 73(1):37–45. doi:10.1016/S0025-6196(11)6366-1

21. Hooper MM, Bogaard HJ, Condiffe R, Frantz R, Khanna D, Kurzyna M, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol (2013) 62(25 Suppl):S42–50. doi:10.1016/j.jacc.2013.10.032

22. Janda S, Quon BS, Swiston J. HIV and pulmonary arterial hypertension: a systematic review. HIV Med (2010) 11(6):620–34. doi:10.1111/j.1468-1293.2010.00829.x

23. Sibton O, Lasoux-Combe C, Delfraissy JF, Yeni PG, Raffi F, De Zuttere D, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med (2003) 167(10):1433–9. doi:10.1164/ajrccm.200204-330OC

24. Opravil M, Pecher M, Speich R, Joller-Jemelka H, Jenni R, Russi EW, et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV cohort study. Am J Respir Crit Care Med (1997) 155(3):990–5. doi:10.1164/ajrccm.155.3.9317037

25. Zuber JP, Calmy A, Evison JM, Hasse B, Wagels T, et al. Pulmonary arterial hypertension related to HIV infection. PLoS Med (2004) 1(8):e121. doi:10.1371/journal.pmed.0010121

26. Nunes H, Humbert M, Sitbon O, Morse JH, Deng Z, Knowles JA, et al. Human immunodeficiency virus infection and pulmonary hypertensive diseases: study of 79 cases at the national hospital of tuberculosis and HIV infection. Bull Soc Pathol Exot (2001) 94(1):23–6.

27. Ten Freyhaus H, Vogel D, Lehnmann C, Kummerle T, Wyen C, Fatkenheuer G, et al. Exhaustive screening for pulmonary arterial hypertension in HIV-positive patients. Infection (2014) 42(4):737–41. doi:10.1007/s15010-014-0610-8

28. Petrosillo N, Cinelli P, Cicalini S. Pulmonary hypertension in individuals with HIV infection. AIDS. (2006) 20(16):2128–9. doi:10.1097/01.aids.0000247569.05504.8b

29. Reinsch N, Buhr C, Krings P, Kaelsch H, Kahlert P, Konorza T, et al. Effect of growth factor expression in primary pulmonary hypertension: comparison with primary pulmonary hypertension. Comparison with primary pulmonary hypertension. Circulation (1994) 89(6):6272–7.

30. Polos PG, Wolfe D, Harley RA, Strange C, Sahn SA. Pulmonary hypertension and human immunodeficiency virus infection. Two reports and a review of the literature. Chest (1992) 101(2):474–8. doi:10.1378/chest.101.2.474

31. Coplan NL, Shimony RJ, Iohomel HI, Wilzent JR, Posner EH, Lipschitz A, et al. Primary pulmonary hypertension associated with human immunodeficiency viral infection. Am J Med (1999) 89(1):96–9. doi:10.1016/S0002-9343(99)90105-M

32. Cool CD, Kennedy D, Voelkel NF, Tudor RM. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with sclerosis and human immunodeficiency virus infection. Hum Pathol (1997) 28(4):434–42. doi:10.1006/hump.1997.0002

33. Mette SA, Palevsky HI, Pietra GG, Williams TM, Bruder E, Prestipino AI, et al. Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am Rev Respir Dis (1992) 145(5):1196–200. doi:10.1164/ajrccm.145.5.1196

34. Heroen E, Laaban JP, Capron F, Quiefelin J, Brechet JM, Rochermaure J. Thrombotic primary pulmonary hypertension in an HIV+ patient. Eur Heart J (1994) 15(3):394–6.

35. Marecki JC, Cool CD, Parr JE, Beckey VE, Lucow PA, Tarantall AF, et al. HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. Am J Respir Crit Care Med (2006) 174(4):437–45. doi:10.1164/rccm.200601-0005OC

36. George MP, Champion HG, Simon M, Guyach S, Tarantelli K, Kling HM, et al. Physiologic changes in a nonhuman primate model of HIV-associated pulmonary arterial hypertension. Am J Respir Cell Mol Biol (2013) 48(3):374–81. doi:10.1165/rcmb.2011-0434OC

37. Humbert M, Monti G, Fartioulis M, Magnan A, Brento F, Rabin B, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J (1998) 11(3):54–9.

38. Pellicelli AM, Palmieri F, D’Ambrosio CS, Rianda A, Boumis E, Girardt E, et al. Role of human immunodeficiency virus in primary pulmonary hypertension – case reports. Angiology (1998) 49(12):1005–10. doi:10.1177/000331979804910206

39. Conly J, Hildes D, Deneer H, Idets I, Mozoya T. Primary pulmonary hypertension and human immunodeficiency virus infection. Can J Infect Dis (1997) 8(5):290–1.

40. Chalifoux LV, Simon MA, Pauley DR, Mackey JI, Wyand MS, Ringler DJ. Arte- riopathy in macaques infected with simian immunodeficiency virus. Lab Invest (1992) 67(3):338–49.

41. Giard A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med (1993) 328(24):1732–9. doi:10.1056/NEJM199309223282402

42. Pellicelli AM, D’Ambrosio CS, Vizza CD, Borgia MC, Tanzi P, Pino P, et al. HIV-related pulmonary hypertension. From pathogenesis to clinical aspects. Acta Cardiol (2004) 59(3):323–30. doi:10.2143/AC.59.3.2005190

43. Kamogne GD, Primeaux C, Grammas P. Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. Biochem Biophys Res Commun (2005) 333(4):1167–175. doi:10.1016/j.bbrc.2005.05.198

44. Ehrenreich H, Rieckmann P, Sinowatz F, Weih KA, Arthur LO, Goebel FD, et al. Potential stimulation of monocyte endothelin-1 production by HIV-1 glycoprotein 120. J Immunol (1993) 150(10):4601–9.

45. Takano Y, Shimokado K, Hata Y, Yoshida M. HIV envelope protein gp120-triggered CD4+ T-cell adhesion to vascular endothelium is regulated via CD4 and CXCxR4 receptors. Biochem Biophys Acta (2007) 1772(5):349–55. doi:10.1016/j.bbis.2007.01.010

46. Schecter AD, Berman AR, Li Y, Mosoian A, McManus CM, Berman JW, et al. HIV envelope gp120 activates human arterial smooth muscle cells. Proc Natl Acad Sci USA (2001) 98(18):10142–7. doi:10.1073/pnas.181328798

47. Lehmann MH, Walter S, Yissagigat L, Streiffel F, Ovod V, Geyer M, et al. Extra- cellular HIV-1 Nef increases migration of monocytes. Exp Cell Res (2006) 312(18):6369–68. doi:10.1016/j.yexcr.2006.08.008

48. Almodovar S, Huse PY, Morelli J, Huang L, Flores SC, Lung HV. Pathogenesis of HIV-associated pulmonary hypertension: potential role of HIV-1 Nef. Proc Am Thorac Soc (2011) 8(3):308–12. doi:10.1513/pats.201006-046WR

49. Almodovar S, Knight R, Aihshouse AA, Boermer S, Lorangepun C, McDonald D, et al. Human immunodeficiency virus nef signature sequences are
associated with pulmonary hypertension. *AIDS Res Hum Retroviruses* (2012) 28(6):607–18. doi:10.1089/AID.2011.2021

57. Hofman FM, Wright AD, Dohdvalwa MM, Wong-Staal F, Walker SM. Exogeneity of TAT protein activates human endothelial cells. *Blood* (1993) 82(9):2774–80.

58. Cota-Gomez A, Flores NC, Cucuz C, Casullo A, Aw TY, Ichikawa H, et al. The human immunodeficiency virus-1 Tat protein activates human umbilical vein endothelial cell E-selectin expression via an NF-kappa B-dependent mechanism. *J Biol Chem* (2002) 277(17):14390–9. doi:10.1074/jbc.M108591200

59. Shiavi P, Sirna MP, Laderer P, Dhillo NK. Downregulation of bone morphogenetic protein receptor axis during HIV-1 and cocaine-mediated pulmonary smooth muscle hyperplasia: implications for HIV-related pulmonary arterial hypertension. *Arterioscler Thromb Vasc Biol* (2013) 33(11):2588–95. doi:10.1161/ATVBAHA.113.302054

60. Porter KM, Walp ER, Elms SC, Raynor R, Mitchell PO, Guidot DM, et al. Primary pulmonary hypertension. *Am J Respir Crit Care Med* (2004) 169(4):411–9. doi:10.1164/ajrccm.162.5.2004042

61. Parikh RV, Scherzer R, Nitta EM, Leone A, Hur S, Mistry V, et al. Increased levels of asymmetric dimethylarginine are associated with pulmonary arterial hypertension. *AIDS* (2001) 15(1):147–8. doi:10.1097/00002030-200010970-00026

62. Ascherl G, Hohenadl C, Schatz O, Shumay E, Bogner J, Eckhart L, et al. Infection of human immunodeficiency virus-1 increases expression of vascular endothelial growth factor in T cells: implications for acquired immunodeficiency syndrome-associated vasculopathy. *Blood* (1999) 93(12):4232–41.

63. Morse JH, Barst RJ, Itescu S, Flaster ER, Sinha G, Zhang Y, et al. Primary pulmonary hypertension in HIV infection: an outcome determined by particular human immunodeficiency virus genotypes. *Clin Infect Dis* (1999) 28(2):495–501. doi:10.1086/327517.62665.ec

64. Recusani F, Di Matteo A, Gambarin F, D’Armini A, Klersy C, Campana C. Highly active antiretroviral therapy combined with a NO donor and bosentan in patients with HIV-associated pulmonary hypertension. *Am J Respir Crit Care Med* (2004) 170(11):1212–7. doi:10.1164/rccm.200404-4450C

65. Garcia-Varela A, Alvarez S, Guzman E, Hernandez E. Regression of HIV-associated pulmonary hypertension following highly active antiretroviral therapy. *Eur Respir J* (2001) 18(6):1089–115. doi:10.1183/09031936.01.00053100

66. Sitbon O, Gressin V, Sprich R, Macdonald PS, Opravil M, Cooper DA, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. *Am J Respir Crit Care Med* (2004) 170(11):1299–301. doi:10.1164/rccm.200407-0747OA

67. Sitbon O, Gressin V, Sprich R, Macdonald PS, Opravil M, Cooper DA, et al. Effects of HIV protease inhibitors on progression of monocrotaline-induced pulmonary hypertension. *Am J Pathol* (2004) 164(4):1212–7. doi:10.1016/S0002-9440(04)02039-7

68. Recusani F, Di Matteo A, Gambarin F, D’Armini A, Klersy C, Campana C. Highly active antiretroviral therapy combined with a NO donor and bosentan in patients with HIV-associated pulmonary hypertension. *Am J Respir Crit Care Med* (2004) 170(11):1299–301. doi:10.1164/rccm.200407-0747OA

69. Sitbon O, Gressin V, Sprich R, Macdonald PS, Opravil M, Cooper DA, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. *Am J Respir Crit Care Med* (2004) 170(11):1299–301. doi:10.1164/rccm.200407-0747OA
Conflict of Interest Statement: The Review Editor Dunbar Ivy declares that, despite having collaborated on publications in the last 2 years with author Maurice Beghetti, the review process was handled objectively. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 17 November 2014; accepted: 19 March 2015; published online: 07 April 2015.

Citation: L’Huillier AG, Pfeif-y-barbe KM, Pictet H and Beghetti M (2015) Pulmonary arterial hypertension among HIV-infected children: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation (2012) 125(1):113–22. doi:10.1161/CIRCULATIONAHA.111.026591

L’Huillier et al. HIV-related pediatric pulmonary arterial hypertension

Conflicts of Interest: The authors declare no conflict of interest.